|Day's Range||1.93 - 2.07|
|52 Week Range||1.53 - 9.09|
|PE Ratio (TTM)||-2.19|
|Earnings Date||Aug 9, 2017 - Aug 14, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||26.00|
The '333 Patent covers methods of capturing exosomes that include an MHC-I or MHC-II antigen, whereby a patient suspected of receiving a benefit from exosome capture and removal is selected, and the whole blood, plasma, or serum from the patient is contacted with a substrate that includes antibodies specific for an MHC-I or MHC-II antigen. The '333 Patent also covers methods of capturing and removing MHC-I or MHC-II antigen associated exosomes from whole blood, plasma, or serum of a patient, and returning the whole blood, plasma, or serum to the patient with substantially fewer MHC-I or MHC-II antigen associated exosomes. MHC-I and MHC-II antigen associated exosomes contribute to the progression of numerous disease conditions, including cancer, autoimmune disorders and neurodegenerative diseases.
Research Desk Line-up: Aethlon Medical Post Earnings Coverage LONDON, UK / ACCESSWIRE / July 7, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for CONMED ...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Aethlon Medical, Inc. Here are 5 ETFs with the largest exposure to AEMD-US. Comparing the performance and risk of Aethlon Medical, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)